Clinical Trial Update: Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients [Phase 2]

View source ↗

Summary

Phase II trial investigating neoadjuvant and adjuvant toripalimab with concurrent chemoradiotherapy in nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN